CHENGDA PHARMA(SZ:301201)2026-01-14 09:18Group 1: Small Nucleic Acid Business - The company's small nucleic acid business primarily includes phosphoramidite monomers and GalNAc delivery systems, with the capability to provide modified monomer processes to meet diverse customer needs [2][3] - Pricing for small nucleic acid monomers varies based on customer requirements, including different segments, quantities, and stages [3] - The company began its small nucleic acid business layout in 2024, driven by overseas agency promotion and technical cooperation [3] Group 2: Supply Chain and Production Capacity - MNC suppliers generally do not change key material suppliers easily due to the need for global registration and product process validation [3] - The company's production capacity is expected to meet the demands of small nucleic acid business as fundraising projects gradually release capacity [3] Group 3: Stem Cell Projects - The company has made progress in its cell therapy projects, including the completion of GMP facility design, installation, and validation for heart and brain infarction projects [3] - Technical transfers for umbilical cord mesenchymal stem cells have been completed, establishing seed, master, and working cell banks, along with method development and validation for analysis [3] Group 4: Investor Relations Activity - The investor relations activity took place on January 14, 2026, from 10:30 to 11:30 in the company meeting room, involving various investment firms [2] - The activity did not involve the disclosure of any undisclosed significant information [3]